For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...
[21] This was a smaller study that enrolled 74 patients 65 years and older with NYHA class II or III heart failure (defined by the Framingham criteria) and an ejection fraction ≥40%. Background ...
Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.
1d
Edgewise Therapeutics announced topline data from Phase 1 and Phase 2 trials of EDG-7500 for obstructive hypertrophic ...
The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...
Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and ...
The medication, finerenone, could be an effective therapy in people with heart failure who have mildly reduced or preserved ejection fraction, suggests the study, published Sunday in the New Engla ...
Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...
Cytokinetics presented positive Phase 1 trial data for CK-586, a potential heart failure treatment, showing safety, ...
The weight-loss jab Wegovy has been hailed as an “absolute game-changer” after a new study showed that it relieved symptoms ...
Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a ...
Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback